Introduction
Kisspeptin neurons have been identified as the key neuroendocrine system in the regulation of the hypothalamic-pituitary-gonadal (HPG) axis, acting one step upstream of gonadotropin-releasing hormone (GnRH) neurons (Smith et al., 2005a (Smith et al., , 2005b Oakley et al., 2009) . GnRH neurons express GPR54, a G-protein coupled receptor targeted by kisspeptin (Lee et al., 1999; Muir et al., 2001; Brailoiu et al., 2005) . A sufficient kisspeptinergic drive to GnRH neurons has been found to be necessary to maintain fertility in human males (Dhillo et al., 2005) and a disruption of this system has been associated with a wide variety of reproductive development problems. For example, inactivating mutations in GPR54 lead to a normosmic form of hypogonadotropic hypogonadism in humans (de Roux et al, 2003; Seminara et al., 2003) and an activating mutation of GPR54 was found to cause precocious puberty (Teles et al., 2008) . In addition, GPR54 knock-out mice fail to make pulsatile luteinizing hormone (LH) and follicle-stimulating hormone secretions and do not undergo puberty (Funes et al., 2003) .
KiSS-1 (encoding kisspeptins) and GPR54 gene expression has been noted in the hypothalamus of nonprimates (Smith et al., 2005a (Smith et al., , 2005b , nonhuman primates (Shahab et al., 2005) , and humans (Muir et al., 2001 ) and has been found to be regulated by a number of mechanisms. For example, season and metabolic status have been shown to regulate the expression of KiSS-1 (Simonneaux et al., 2009; Wahab et al., 2011) . Sex hormones have also been found to regulate the expression of KiSS-1 mRNA in the periventricular nucleus and anteroventral periventricular nucleus of both male and female mice (Smith et al., 2005a (Smith et al., , 2005b . Interestingly, gonadectomy was found to increase KiSS-1 mRNA levels in the arcuate nucleus of rats, and this increased transcription was lowered with sex steroid replacement (Navarro et al., 2004) . This evidence suggested the existence of a feedback mechanism involved in the regulation of kisspeptin transcription, expression, and secretion, which might ultimately regulate reproductive function.
The pivotal role of kisspeptin-GPR54 signaling in reproductive function has been demonstrated in a number of pharmacological (Shahab et al., 2005; Wahab et al., 2010) and gene expression (Brown et al., 2008) studies. However, the physiological significance of this signaling has not been well characterized. This may be due to the lack of physiological evidence, which had been difficult to ascertain because of the absence of a potent kisspeptin antagonist. In recent years, the discovery of a kisspeptin antagonist, peptide 234 (P234), and its use in animal investigations has helped to shed light on the role of endogenous kisspeptin signaling in regulating the reproductive axis. These studies have provided detailed evidence for a physiological role of kisspeptin signaling in regulating GnRH secretion in mammals (Shahab et al., 2005; Brown et al., 2008; Roseweir et al., 2009; Wahab et al., 2010; Pineda et al., 2010; Guerriero et al., 2012) . However, few studies have been directed at examining testosterone release in primates in response to peripheral kisspeptin, and the few studies that have used P234 have predominantly administered the antagonist centrally within the nervous system. Although these studies have provided fruitful information into the role of kisspeptin signaling, they have been limited in investigating kisspeptin's peripheral effect within the body. For example, Roseweir et al. (2009) found that the central administration of the kisspeptin antagonist inhibited the firing rate of GnRH neurons in mouse brain slices, reduced pulsatile GnRH secretion in female pubertal monkeys, and inhibited kisspeptin-induced release of LH in rats and mice; they also found that P234 administration blocked castration-induced rises of LH levels in sheep, rats, and mice. Furthermore, the central infusion of P234 has been found to inhibit the onset of puberty and to block the preovulatory surge of LH in female rats (Pineda et al., 2010) .
Only a few studies have used the peripheral administration of kisspeptin antagonists (P234, P271). These include the peripheral administration (intraperitoneal) of P234 and P271 (P234 conjugated to penetratin to enhance transport across the blood-brain barrier) in rats, with the finding that the P271 blocked kisspeptin-dependent LH release (Pineda et al., 2010) . Other studies that have used similar administration of P271 to investigate kisspeptin-GnRH signaling have found that P271 blunted gonadotropin response to kisspeptin-10 in rats (Pineda et al., 2010) and suppressed GnRH release in prepubertal female monkeys (Guerriero et al., 2012) . Furthermore, none of these studies examined testosterone release in response to the peripheral action of kisspeptin.
The present study was specifically designed to investigate the physiological role of endogenous kisspeptin in the regulation of testosterone secretion in the adult male rhesus monkey using the intravenous injection of P234.
Materials and methods

Animals
Five intact adult male rhesus monkeys (Macaca mulatta), 6-8 years old and weighing 8.5-15.5 kg, were used for the current study. These animals were housed in individual cages under standard colony conditions in the primate facility of the Department of Animal Sciences, Quaid-iAzam University. The animals were fed daily with fresh fruits (0900-0930 hours), hardboiled eggs (1100 hours), and bread (1300-1330 hours). Water was available ad libitum. Appetite was monitored for 1 month prior to the beginning of the experiments. In order to reduce the effects of stress on the blood sampling, the animals were habituated to the chair restraint 2 months prior to commencing the experiments. The duration of restraint was gradually increased until a daily period of 3 h was attained. The animals were sedated with ketamine hydrochloride (Ketler, Astarapin, Germany; 5 mg/kg BW, intramuscularly) for placement in and removal from the restraining chair. All experimental protocols of the present study were approved by the Department of Animal Science Committee for Care and Use of Laboratory Animals, Quaid-i-Azam University. Furthermore, all the animals were kept according to the ethical standards for the treatment of animals within the guidelines laid down by the Primate Society of Japan, the National Institutes of Health (USA), the EC Guide for Animal Experiments, and the guidelines of the Wild Life Department and other specific national laws.
Venous catheterization
To permit sequential withdrawal of blood samples and intravenous administration of kisspeptin-10 and the kisspeptin antagonist, the animals were anesthetized with ketamine (10 mg/kg BW, intramuscularly) and a Teflon cannula (Vasocan Branule, 0.8 mm/22 G, B. Braun Melsungen, Germany) was inserted into the saphenous vein. The distal end of the cannula was attached to a syringe via a butterfly tube (length 300 mm, volume 0.29 mL, 20 GX3, JMS, Singapore). Experiments were not initiated until the animals had fully recovered from sedation.
Pharmacological agents
Ketamine and heparin (Rotex Medica, Germany) were purchased from local distributors. Human kisspeptin-10 (112-121; KP-10) was purchased from Calbiochem (USA). The kisspeptin antagonist, P234, was purchased from Sigma-Aldrich (USA). Working solutions of KP-10 and P234 were made in normal saline (0.9% NaCl).
Experimental design
The first experiment was designed to measure the effect of a kisspeptin receptor blockade on basal plasma testosterone levels in adult male rhesus monkeys. The animals (n = 5) were blood-sampled at 15-min intervals for a total period of 420 min. The animals were injected with saline (0.9 % NaCl) as a vehicle after getting the sample at 60 min. One week later, the same animals were injected with P234 (using a similar protocol and sampled as described above) as a single bolus intravenous injection (38.8 µg/kg body weight) after 60 min. The dose of P234 was calculated based on a previously administered dose of P234 applied centrally in female monkeys (Roseweir et al., 2009 ). The peripheral dose used here was 10-fold higher than the previous dose administered centrally. On a separate occasion, a 60-min infusion of P234, 60 mL (38.8 µg/kg body weight) at the rate of 1 mL/min, was infused in the saphenous vein for testing in 1 animal.
In a second experiment, the effect of the kisspeptin antagonist on testosterone response to KP-10 was evaluated in adult male rhesus monkeys (n = 3) by systemically delivering the antagonist prior to KP-10 stimulation. Each animal was given a bolus intravenous injection of P234 (38.8 µg/kg BW) followed by an intravenous KP-10 injection (50 µg) 30 min later. For control sampling, 1 week earlier than the treatment, the same animals received the vehicle followed by a KP-10 injection. Blood samples were collected at 15-min intervals for 60 min before P234/ vehicle administration and until 210 min after the KP-10 administration. As mentioned above, the doses of P234 and KP-10 were calculated based on previous work in adult female (Roseweir et al., 2009 ) and adult male (Wahab et al., 2010) rhesus monkeys, respectively. 2.5. Blood sampling Sequential blood samples (2 mL) were obtained in heparinized syringes. Following withdrawal of each sample, an equal amount of heparinized (5 IU/mL) normal saline was administered to avoid blood loss and to keep the cannula patent. Blood sampling was conducted between 1000 and 1800 hours. Blood sampling for the first experiment was done on 19 and 27 October 2010, while blood sampling for the second experiment was done on 3 and 10 November 2010. Blood samples were centrifuged at 3000 rpm for 15 min at 4 °C, and plasma was separated and stored at -20 °C until hormonal analysis. 2.6. Hormone assays Plasma testosterone (T) levels were measured using a commercial testosterone ELISA kit (BioCheck, Inc., USA). The sensitivity of the assay was 0.025 ng/mL. Intra-and interassay coefficients of variation for the testosterone assay were 4.4% and 10%, respectively. Plasma adiponectin levels were measured using the AssayMax human adiponectin ELISA kit (Assaypro, USA). The sensitivity of the assay was 0.5 ng/mL. Intra-and interassay coefficients of variation for the adiponectin assay were 4.1% and 7.2%, respectively. The assays were performed following the manufacturer's instructions.
Statistical analysis
Statistical comparisons for the mean plasma levels of T and adiponectin during pre-and post-P234 periods were made by paired Student's t-tests. Changes in T concentrations observed after administering P234 were assessed by repeated-measures ANOVA followed by Dunnett's multiple comparison test. All data are presented as mean ± SEM. Differences were considered statistically significant at P < 0.05.
Results
Effect of peripheral administration of P234 on plasma testosterone levels
Changes in plasma T levels in pre-and post-P234 injection periods are shown in Figure 1a . Repeated-measure ANOVA showed no effect of vehicle or P234 on mean T levels. Mean plasma T levels observed before and after intravenous injection of p234 were comparable as there was no significant difference (Figure 1b) . Similarly, a 60-min infusion of P234 in 1 animal was not observed to affect plasma T levels (data not shown).
Effect of peripheral administration of p234 on KP-10-induced testosterone release
Temporal changes in plasma T concentrations after the KP-10 administration in monkeys pretreated with P234 or vehicle are shown in Figure 2a . Mean plasma T levels were significantly increased (P < 0.001) in the vehicletreated animals at 105, 120, 135, 150, 180, 195 , and 210 min following KP-10 administration, whereas the plasma T levels were found to be significantly increased (P < 0.001) in the P234-treated group at 90 and 105 min only. Comparison of mean pre-and post-KP-10 T levels by t-test revealed that the KP-10 injection significantly (P < 0.05) increased the mean plasma T levels in the vehicletreated animals, but no significant (P > 0.05) changes were found in the mean plasma T levels after a KP-10 injection in P234-treated animals (Figure 2b ).
Effect of peripheral administration of peptide 234 on plasma adiponectin level
The effect of the kisspeptin receptor blockade on plasma adiponectin levels was used as a positive control for the peripheral effects of kisspeptin, as kisspeptin had been found previously to act peripherally to increase adiponectin secretion (Wahab et al., 2010) .
Mean basal plasma adiponectin levels obtained between -30 and 150 min were found to be significantly decreased in the P234-treated animals, while no significant decrease in plasma adiponectin levels was observed in vehicletreated animals (Figure 3a) . Adiponectin concentrations in blood found after kisspeptin stimulation were significantly reduced following P234 antagonist treatment in comparison to vehicle pretreatment (P < 0.0034; Figure  3b ).
Discussion
This study assessed, for the first time, the effect of the peripheral administration of P234, a GPR54 antagonist, in adult male rhesus monkeys on plasma levels of testosterone, the terminal endocrine signal of the HPG axis. The experimental results demonstrated that the bolus peripheral administration of P234 did not affect basal testosterone release in the monkeys. These results are in line with previous data demonstrating that basal LH levels in adult male rats and basal GnRH levels in adult female rhesus monkey were not affected by the central administration of the P234 (Roseweir et al., 2009) .
The results presented here also indicated that the systemic delivery of P234 abated the testosterone response to kisspeptin, although P234 did not fully abolish kisspeptin-dependent testosterone release. This demonstrates that P234 was indeed antagonizing the GPR54 in this study; an acute central bolus dose of P234 has been shown to similarly inhibit the kisspeptin-dependent LH release in intact male rats and mice (Roseweir et al., 2009) . LH is subsequently responsible for the testosterone release from the Leydig cells of the testis (Saez, 1994) . In castrated male rats and mice, P234 was found to inhibit the postcastration LH increase, which showed that P234 blocked GPR54 receptors centrally. Additionally, penetratin-mixed P234 (P271) administered peripherally abolished the kisspeptin-dependent LH release in adult male rats (Pineda et al., 2010) , which suggested that peripheral administration of P234 could cross the bloodbrain barrier (BBB) in the presence of penetratin, an agent that helps transport macromolecules across the BBB. In this study, kisspeptin-induced testosterone secretion was also found to be considerably reduced by the peripheral administration of P234 without penetratin. However, this reduction was not a complete inhibition of testosterone release, which suggested that the P234 did not have a robust effect. Although there have been preliminary reports of the presence of GPR54 in the monkey testis (Irfan et al., 2008; Tariq et al., 2010) , initial findings from our laboratory have . a) Time course of plasma testosterone levels (mean ± SEM) before and after vehicle or P234 intravenous bolus injection (38.8 µg/kg BW; arrow) in adult male rhesus monkeys (n = 5). Repeated-measure ANOVA showed no effect of the vehicle or antagonist on mean T levels. b) Comparison of mean ± SEM T levels prior to (-60 to 0 min) and after (15-360 min) injection of p234 or vehicle. Mean T levels remained comparable after vehicle and P234 administration.
indicated that kisspeptin does not stimulate testosterone release from monkey testicular tissue fragments in vitro (Tariq and Shahab, unpublished data) . This indicated that kisspeptin may not directly interact with testicular tissue and that the regulation of testosterone release was independent of any peripheral action by kisspeptin. Therefore, the moderate inhibitory effect of P234 on kisspeptin-dependent testosterone release observed in the present study was likely due to a central perturbation, despite it not being certain to what extent the P234 peptide crossed the BBB. Kisspeptin receptors have been shown to be located on the GnRH fibers in the median eminence (ME) region outside the BBB (Inoue et al., 2008) . Similarly, GnRH fibers originating in the monkey hypothalamus that project outside the BBB to the ME have been shown to be contacted by kisspeptin fibers in the ME (Ramaswamy et al., 2008) . Therefore, it is possible that the P234 could access kisspeptin receptors in the ME without passing the BBB in this study. The finding that a partial inhibition of testosterone release was found in P234-treated monkeys suggests that some of the P234 acted on the ME and blocked GPR54 stimulation, which was potentially responsible for the impaired testosterone release. It is likely that the peripherally administered P234 might not have crossed the BBB and could not block GPR54 at sites afferent to GnRH neurons; hence, P234 had no effect on basal testosterone secretion in the present study and/or on basal LH secretion in other studies (Roseweir et al., 2009) . On the other hand, the peripherally administered P234 may have blocked GPR54 on GnRH fibers in the Figure 2. a) KP-10 (50 µg) intravenous bolus injection significantly increased the basal levels of plasma T (mean ± SEM) in the vehicle-treated adult male rhesus monkeys (n = 3). Conversely, only a slight and short, albeit significant, elevation change was observed in the plasma T levels in P234 (38.8 µg/kg BW)-treated animals (n = 3). b) Comparison of mean ± SEM plasma T before (checkered bars) and after (black bars) KP-10 (50 µg, intravenous) in vehicle-or P234-treated adult monkeys (n = 3) revealed that the stimulatory effect of KP-10 on plasma T was no longer significant following P234 pretreatment. ME, which may have provided enough of an effect to significantly reduce kisspeptin-induced testosterone release, but not strong enough to completely abolish the stimulated testosterone release.
Our previous study indicated that the kisspeptin significantly increased plasma adiponectin levels in the adult male rhesus monkey (Wahab et al., 2010) . This was a novel finding and suggested that kisspeptin acted peripherally on adipose tissues and stimulated adiponectin release. In this study, consistent with our earlier findings, it was observed that basal and kisspeptinstimulated adiponectin levels were decreased following a peripheral administration of P234. These findings suggest that peripheral P234 could access adipocyte GPR54 and was able to reduce adiponectin release accordingly. The potential for the P234 bolus injection to cause a reduction in plasma adiponectin levels and to impair the kisspeptindependent adiponectin release in the current study is indicative that P234 did not need to cross the BBB in order to produce antagonistic effects on the kisspeptinadiponectin system. Overall, this study described the effect of peripheral administration of P234 on plasma testosterone and adiponectin levels in adult male rhesus monkeys. The results indicated that P234 moderately reduced the testosterone response to kisspeptin but did not affect basal testosterone levels. These findings suggest that P234 administration modulated the ME kisspeptin-GPR54 signaling involved in kisspeptin-stimulated testosterone release and may have not crossed the BBB. In addition, peripheral kisspeptin signaling could be modulated by P234 and was found important for adiponectin secretary function in adult male monkeys as the P234 administration was also found to decrease adiponectin levels and kisspeptin-dependent adiponectin response. In summary, the current results suggest that kisspeptin signaling provides regulation of testosterone-dependent reproductive function in male primates in a manner that is regulated predominately through the central neuroendocrine system. It is also suggested that peripheral kisspeptin signaling plays an important role in the regulation of adipokine secretion in higher primates.
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